Proteolysis-targeting chimeras (PROTACs) and molecular glue degraders (MGDs) are essentially the most maturely developed TPD methods. On this evaluate, we concentrate on the two preclinical experiments and medical trials to offer an extensive summary of the protection and scientific performance of PROTACs and MGDs in hematologic malignancies in the